XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Jun. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Collaboration And Other Agreements [Line Items]          
Revenues $ 11,101 $ 16,881      
Deferred revenue, current 25,562     $ 20,646  
Deferred revenue, net of current portion 6,364     0  
I-Mab | I-Mab Biopharma Collaboration and License Agreement          
Collaboration And Other Agreements [Line Items]          
Non-refundable upfront payment     $ 15,000    
Potential development and regulatory milestone payments under agreement         $ 135,000
Development and regulatory milestones recognized 5,000     5,000  
Estimated variable consideration     $ 1,000    
Revenues 200 $ 600      
Deferred revenue 4,400     4,500  
One Time Millstone Credit       $ 4,500  
I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum          
Collaboration And Other Agreements [Line Items]          
Potential proceeds from royalties (percent)     20.00%    
I-Mab | I-Mab Biopharma Collaboration And License Agreement Clinical Supply          
Collaboration And Other Agreements [Line Items]          
Revenues $ 900